Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol (2016) 0.85

Cost-effectiveness thresholds: pros and cons. Bull World Health Organ (2016) 0.81

The cost and value of cancer drugs - are new innovations outpacing our ability to pay? Isr J Health Policy Res (2016) 0.79

Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. J Virol (2017) 0.75

Affordability of medicines in the European Union. PLoS One (2017) 0.75

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One (2017) 0.75

Defining and Measuring the Affordability of New Medicines: A Systematic Review. Pharmacoeconomics (2017) 0.75

The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. Clinicoecon Outcomes Res (2017) 0.75

Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs? J Clin Exp Hepatol (2017) 0.75

When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Med (2017) 0.75

Risk behaviour determinants among people who inject drugs in Stockholm, Sweden over a 10-year period, from 2002 to 2012. Harm Reduct J (2017) 0.75

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2014) 26.76

Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet (2008) 11.56

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48

Side effects of therapy of hepatitis C and their management. Hepatology (2002) 5.18

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood (2013) 4.85

Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol (2014) 4.82

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology (2010) 4.46

Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80

A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc (2010) 2.25

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med (2015) 2.14

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07

Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc (2011) 1.88

The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Intern Med (2014) 1.78

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66

Differences in external price referencing in Europe: a descriptive overview. Health Policy (2011) 1.45

Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia (2012) 1.28

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05

Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health (2015) 1.03

Discounts and rebates granted to public payers for medicines in European countries. South Med Rev (2012) 1.02

Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. Health Policy Plan (2012) 0.92

Mixed HCV infection and reinfection in people who inject drugs--impact on therapy. Nat Rev Gastroenterol Hepatol (2015) 0.89

Income level and drug related harm among people who use injection drugs in a Canadian setting. Int J Drug Policy (2013) 0.85

The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012. Ir Med J (2015) 0.81

A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. J Urban Health (2015) 0.78

Access to critical medicines: When are compulsory licenses effective in price negotiations? Soc Sci Med (2015) 0.77

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut (2015) 0.93

World Hepatitis Day 2013: know it, confront it. Lancet Glob Health (2013) 0.75